Sunday 11 October 2026
Export all EQ data to Excel Powerpack
Equillium, Inc.
Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.
1.41
0.03
−2.08%
Follow EQ
Equillium, Inc. (EQ) P/E ratio
Equillium, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| EQ Equillium, Inc. | n/m |
| CLLS Cellectis S.A. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| RLYB Rallybio Corporation compare | 2.1× |
| VXRT VAXART, INC. compare | 2.8× |
| ICCC ImmuCell Corporation compare | 114× |
| Biotechnology industry median | 8.7× |
| Healthcare sector median | 22.5× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)